BRISTOL-MYERS SQUIBB COMPANY Restructuring Costs and Asset Impairment Charges
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Restructuring Costs and Asset Impairment Charges of -$32.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY restructuring costs and asset impairment charges for the quarter ending 2026-06-30 was -$32.00M, a 111.47% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY restructuring costs and asset impairment charges for the quarter ending 2026-03-31 was $1.00M, a 99.47% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY restructuring costs and asset impairment charges for the quarter ending 2025-12-31 was $225.00M, a 13.07% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY restructuring costs and asset impairment charges for the quarter ending 2025-09-30 was $232.00M, a 11.79% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY restructuring costs and asset impairment charges for fiscal 2025 was $926.00M, a 18.13% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY restructuring costs and asset impairment charges for fiscal 2024 was $1.13B, a 45.56% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY restructuring costs and asset impairment charges for fiscal 2023 was $777.00M, a 49.42% increase from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY restructuring costs and asset impairment charges for fiscal 2022 was $520.00M, a 30.76% decline from fiscal 2021.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 3 month as first filed | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$32.00M 10-Q · filed 2026-07-30 | -$31.00M 10-Q · filed 2026-07-30 | $194.00M derived: sum of 3 quarters · filed 2026-07-30 | $426.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $1.00M 10-Q · filed 2026-04-30 | $226.00M derived: sum of 2 quarters · filed 2026-04-30 | $458.00M derived: sum of 3 quarters · filed 2026-04-30 | $737.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $225.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $457.00M derived: sum of 2 quarters · filed 2026-02-11 | $736.00M derived: sum of 3 quarters · filed 2026-07-30 | $926.00M 10-K · filed 2026-02-11 | |
| 2025-09-30 | $232.00M 10-Q · filed 2025-10-30 | $511.00M derived: sum of 2 quarters · filed 2026-07-30 | $701.00M 10-Q · filed 2025-10-30 | $900.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $279.00M 10-Q · filed 2026-07-30 | $469.00M 10-Q · filed 2026-07-30 | $668.00M derived: sum of 3 quarters · filed 2026-07-30 | $931.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $190.00M 10-Q · filed 2026-04-30 | $389.00M derived: sum of 2 quarters · filed 2026-04-30 | $652.00M derived: sum of 3 quarters · filed 2026-04-30 | $1.01B derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $199.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $462.00M derived: sum of 2 quarters · filed 2026-02-11 | $819.00M derived: sum of 3 quarters · filed 2026-02-11 | $1.13B 10-K · filed 2026-02-11 | |
| 2024-09-30 | $263.00M 10-Q · filed 2025-10-30 | $620.00M derived: sum of 2 quarters · filed 2025-10-30 | $932.00M 10-Q · filed 2025-10-30 | $1.06B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-06-30 | $357.00M 10-Q · filed 2025-07-31 | $669.00M 10-Q · filed 2025-07-31 | $797.00M derived: sum of 3 quarters · filed 2026-02-11 | $1.08B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-03-31 | $312.00M 10-Q · filed 2025-04-24 | $440.00M derived: sum of 2 quarters · filed 2026-02-11 | $720.00M derived: sum of 3 quarters · filed 2026-02-11 | $954.00M derived: sum of 4 quarters · filed 2026-02-11 | |
| 2023-12-31 | $128.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $408.00M derived: sum of 2 quarters · filed 2026-02-11 | $642.00M derived: sum of 3 quarters · filed 2026-02-11 | $777.00M 10-K · filed 2026-02-11 | |
| 2023-09-30 | $280.00M 10-Q · filed 2024-10-31 | $514.00M derived: sum of 2 quarters · filed 2024-10-31 | $649.00M 10-Q · filed 2024-10-31 | $760.00M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-06-30 | $234.00M 10-Q · filed 2024-07-26 | $369.00M 10-Q · filed 2024-07-26 | $480.00M derived: sum of 3 quarters · filed 2025-02-12 | $611.00M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-03-31 | $135.00M 10-Q · filed 2024-04-25 | $246.00M derived: sum of 2 quarters · filed 2025-02-12 | $377.00M derived: sum of 3 quarters · filed 2025-02-12 | $525.00M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2022-12-31 | $111.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $242.00M derived: sum of 2 quarters · filed 2025-02-12 | $390.00M derived: sum of 3 quarters · filed 2025-02-12 | $520.00M 10-K · filed 2025-02-12 | |
| 2022-09-30 | $131.00M 10-Q · filed 2023-10-26 | $279.00M derived: sum of 2 quarters · filed 2023-10-26 | $409.00M 10-Q · filed 2023-10-26 | $560.00M derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-06-30 | $148.00M 10-Q · filed 2023-07-27 | $278.00M 10-Q · filed 2023-07-27 | $429.00M derived: sum of 3 quarters · filed 2024-02-13 | $600.00M derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-03-31 | $130.00M 10-Q · filed 2023-04-27 | $281.00M derived: sum of 2 quarters · filed 2024-02-13 | $452.00M derived: sum of 3 quarters · filed 2024-02-13 | $671.00M derived: sum of 4 quarters · filed 2024-02-13 | |
| 2021-12-31 | $151.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $322.00M derived: sum of 2 quarters · filed 2024-02-13 | $541.00M derived: sum of 3 quarters · filed 2024-02-13 | $751.00M 10-K · filed 2024-02-13 | |
| 2021-09-30 | $171.00M 10-Q · filed 2022-10-26 | $390.00M derived: sum of 2 quarters · filed 2022-10-26 | $600.00M 10-Q · filed 2022-10-26 | $881.00M derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-06-30 | $219.00M 10-Q · filed 2022-07-27 | $429.00M 10-Q · filed 2022-07-27 | $710.00M derived: sum of 3 quarters · filed 2023-02-14 | $1.09B derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-03-31 | $210.00M 10-Q · filed 2022-04-29 | $491.00M derived: sum of 2 quarters · filed 2023-02-14 | $874.00M derived: sum of 3 quarters · filed 2023-02-14 | $1.21B derived: sum of 4 quarters · filed 2023-02-14 | |
| 2020-12-31 | $281.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $664.00M derived: sum of 2 quarters · filed 2023-02-14 | $1.00B derived: sum of 3 quarters · filed 2023-02-14 | $1.41B 10-K · filed 2023-02-14 | |
| 2020-09-30 | $383.00M 10-Q · filed 2021-10-27 | $723.00M derived: sum of 2 quarters · filed 2021-10-27 | $1.13B 10-Q · filed 2021-10-27 | $1.86B derived: sum of 4 quarters · filed 2022-02-09 | |
| 2020-06-30 | $340.00M 10-Q · filed 2021-07-28 | $746.00M 10-Q · filed 2021-07-28 | $1.48B derived: sum of 3 quarters · filed 2022-02-09 | $1.53B derived: sum of 4 quarters · filed 2022-02-09 | |
| 2020-03-31 | $406.00M 10-Q · filed 2021-04-29 | $1.14B derived: sum of 2 quarters · filed 2022-02-09 | $1.19B derived: sum of 3 quarters · filed 2022-02-09 | $1.34B derived: sum of 4 quarters · filed 2022-02-09 | |
| 2019-12-31 | $732.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $784.00M derived: sum of 2 quarters · filed 2022-02-09 | $935.00M derived: sum of 3 quarters · filed 2022-02-09 | $979.00M 10-K · filed 2022-02-09 | |
| 2019-09-30 | $52.00M 10-Q · filed 2019-10-31 | $203.00M derived: sum of 2 quarters · filed 2019-10-31 | $247.00M 10-Q · filed 2019-10-31 | $315.00M derived: sum of 4 quarters · filed 2021-02-10 | |
| 2019-06-30 | $151.00M 10-Q · filed 2019-07-25 | $195.00M 10-Q · filed 2019-07-25 | $263.00M derived: sum of 3 quarters · filed 2021-02-10 | $339.00M derived: sum of 4 quarters · filed 2021-02-10 | |
| 2019-03-31 | $44.00M 10-Q · filed 2019-04-25 | $112.00M derived: sum of 2 quarters · filed 2021-02-10 | $188.00M derived: sum of 3 quarters · filed 2021-02-10 | $258.00M derived: sum of 4 quarters · filed 2021-02-10 | |
| 2018-12-31 | $68.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $144.00M derived: sum of 2 quarters · filed 2021-02-10 | $214.00M derived: sum of 3 quarters · filed 2021-02-10 | $268.00M 10-K · filed 2021-02-10 | |
| 2018-09-30 | $76.00M 10-Q · filed 2019-10-31 | $146.00M derived: sum of 2 quarters · filed 2019-10-31 | $200.00M 10-Q · filed 2019-10-31 | $456.00M derived: sum of 4 quarters · filed 2019-10-31 | |
| 2018-06-30 | $70.00M 10-Q · filed 2019-07-25 | $124.00M 10-Q · filed 2019-07-25 | $380.00M derived: sum of 3 quarters · filed 2019-07-25 | $473.00M derived: sum of 4 quarters · filed 2019-07-25 | |
| 2018-03-31 | $54.00M 10-Q · filed 2019-04-25 | $20.00M 10-Q · filed 2018-04-26 | $310.00M derived: sum of 2 quarters · filed 2019-04-25 | $403.00M derived: sum of 3 quarters · filed 2019-04-25 | $644.00M derived: sum of 4 quarters · filed 2019-04-25 |
| 2017-12-31 | $256.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $349.00M derived: sum of 2 quarters · filed 2019-02-25 | $590.00M derived: sum of 3 quarters · filed 2019-02-25 | $826.00M 10-K · filed 2019-02-25 | |
| 2017-09-30 | $93.00M 10-Q · filed 2018-10-25 | $334.00M derived: sum of 2 quarters · filed 2018-10-25 | $570.00M 10-Q · filed 2018-10-25 | $615.00M derived: sum of 4 quarters · filed 2019-02-25 | |
| 2017-06-30 | $241.00M 10-Q · filed 2018-07-26 | $477.00M 10-Q · filed 2018-07-26 | $522.00M derived: sum of 3 quarters · filed 2019-02-25 | $562.00M derived: sum of 4 quarters · filed 2019-02-25 | |
| 2017-03-31 | $164.00M 10-Q · filed 2018-04-26 | $236.00M 10-Q · filed 2017-04-27 | $281.00M derived: sum of 2 quarters · filed 2019-02-25 | $321.00M derived: sum of 3 quarters · filed 2019-02-25 | $356.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $117.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $157.00M derived: sum of 2 quarters · filed 2019-02-25 | $192.00M derived: sum of 3 quarters · filed 2019-02-25 | $213.00M 10-K · filed 2019-02-25 | |
| 2016-09-30 | $40.00M 10-Q · filed 2017-10-26 | $75.00M derived: sum of 2 quarters · filed 2017-10-26 | $96.00M 10-Q · filed 2017-10-26 | ||
| 2016-06-30 | $35.00M 10-Q · filed 2017-07-27 | $56.00M 10-Q · filed 2017-07-27 | |||
| 2016-03-31 | $21.00M 10-Q · filed 2017-04-27 | ||||
| 2015-12-31 | $233.00M 10-K · filed 2018-02-13 | ||||
| 2014-12-31 | $314.00M 10-K · filed 2017-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |